Synergistic Effect of a HER2 Targeted Thorium-227 Conjugate in Combination with Olaparib in a BRCA2 Deficient Xenograft Model

• Main Authors: Katrine Wickstroem (Author), Jenny Karlsson (Author), Christine Ellingsen (Author), Véronique Cruciani (Author), Alexander Kristian (Author), Urs B. Hagemann (Author), Roger M. Bjerke (Author), Olav B. Ryan (Author), Lars Linden (Author), Dominik Mumberg (Author), Michael Brands (Author), Alan Cuthbertson (Author)
• Format: Book
• Published: MDPI AG, 2019-10-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Targeted thorium-227 conjugates (TTCs) represent a novel class of therapeutic radiopharmaceuticals for the treatment of cancer. TTCs consist of the alpha particle emitter thorium-227 complexed to a 3,2-hydroxypyridinone chelator conjugated to a tumor-targeting monoclonal antibody. The high energy an...